Cargando…

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)

Background: Despite the increasing global adverse health impact of obesity, there are few pharmacological options for effective weight management. STEP 1 investigated the efficacy and safety of the glucagon-like peptide-1 analogue, subcutaneous (s.c.) semaglutide, for weight management in adults wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilding, John P H, Batterham, Rachel L, Calanna, Salvatore, Davies, Melanie, Van Gaal, Luc F, Lingvay, Ildiko, McGowan, Barbara M, Rosenstock, Julio, Tran, Marie T D, Wadden, Thomas A, Wharton, Sean, Yokote, Koutaro, Zeuthen, Niels, Kushner, Robert F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089593/ http://dx.doi.org/10.1210/jendso/bvab048.018

Ejemplares similares

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS
por: Jensterle, Mojca, et al.
Publicado: (2022)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
por: Wilding, John P. H., et al.
Publicado: (2022)

Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial
por: Fox, Claudia K, et al.
Publicado: (2021)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

OR04-05 MYOD1 Is Associated with Eosinophil-Mediated Browning of Subcutaneous Adipose Tissue
por: Li, Ting, et al.
Publicado: (2020)

Laminin-α4 Is Uniquely Upregulated in Subcutaneous White Adipose Tissue in Murine and Human Models of Obesity
por: Goddi, Anna, et al.
Publicado: (2021)

MON-118 Biochemical and Clinical Correlates of Subcutaneous Adipose mRNA Transcript Levels in Men with T2DM
por: Tun, Nyo Nyo, et al.
Publicado: (2019)

OR01-4 Mast Cells and Human Adipose Beiging: Mast Cells Are Recruited to Subcutaneous White Adipose and Degranulate in Response to Cold
por: Kern, Philip, et al.
Publicado: (2019)

RF24 | PSUN94 Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Woloschak, Michael, et al.
Publicado: (2022)

SUN-LB106 The Transcriptomic Evidences on Role of Abdominal Visceral vs. Subcutaneous Adipose Tissue in the Pathophysiology of Diabetes in Asian Indian Indicates the Involvement of Both
por: Mathur, Sandeep Kumar, et al.
Publicado: (2020)

OR10-2 Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Abuzzahab, Jennifer, et al.
Publicado: (2022)

MON-598 Vitamin B12 Deficiency Leads to Fatty Acid Metabolism Dysregulation and Increased Pro-Inflammatory Cytokine Production in Human Adipocytes and Maternal Subcutaneous and Omental Adipose Tissue
por: Samavat, Jinous, et al.
Publicado: (2020)

The Effectiveness of Adding Pharmacotherapy to Dietary Counseling for Veterans in a Veterans Health Administration Move! Weight Management Program
por: Alvarez, Diego Alcaraz, et al.
Publicado: (2021)

Anti-Obesity Medication Prescriptions by Race/Ethnicity and Use of an Interpreter in a Pediatric Weight Management Clinic
por: Bomberg, Eric M, et al.
Publicado: (2021)

FRI005 Appetite Response To Short-term Energy Restriction In Young Healthy Women
por: Choi, Gloria E, et al.
Publicado: (2023)

FRI046 Clinical Phenotyping Of Adults With Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2023)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Hair Cortisol, Obesity and the Immune System: Results From a 3 Year Longitudinal Study
por: van der Valk, Eline S, et al.
Publicado: (2021)

The Relation Between Cortisol and Anthropometric Measurements Throughout Lifespan: A Systematic Review and Meta-Analysis
por: van der Valk, Eline S, et al.
Publicado: (2021)

SAT-LB020 Use of Ultrasound to Characterize Abdominal Adipose Tissue Distribution and Its Impact on Metabolic Syndrome
por: Cuatrecasas Cambra, Guillem, et al.
Publicado: (2019)

MON-099 Age-Related Differences in Appetite Regulation among Adults with Obesity: More Than Just Hunger and PYY and Ghrelin? Oh My!
por: Iwamoto, Sean, et al.
Publicado: (2019)

MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
por: Jalal Eldin, Abdelwahab, et al.
Publicado: (2019)

MON-114 Effect of Selective Mineralocorticoid Receptor Antagonist on liver Fat and Metabolism in Patients with Type 2 Diabetes: A Randomized Controlled Trail
por: Kistorp, Caroline, et al.
Publicado: (2019)

MON-092 Role of Genetic Variants of NNMT rs694539 and rs1941404, FTO rs1421085 and Irx3 rs3751723 Polymorphisms on Resting Energy Expenditure and BMI
por: Bañales Luna, Maciel, et al.
Publicado: (2019)

MON-113 Taste Sensitivity is Related to Incretin Response to Oral Glucose Challenge, Dietary Habits and Body Composition: A Novel Link with Energy Metabolism
por: Dagdelen, Selcuk, et al.
Publicado: (2019)

MON-106 Prevalence of Abdominal Obesity According to Different Cutoff Points in the Peruvian Population Living at Different Altitudes
por: Pajuelo-Ramirez, Jaime, et al.
Publicado: (2019)

MON-115 Acute BAT Activation Improves Glucose Tolerance and Beta-Cell Secretion and Facilities Lipid over Glucose Utilization in Obese Metabolically Healthy Males
por: Bertozzi, Beatrice, et al.
Publicado: (2019)

MON-098 FSH and Body Composition in Older Adults
por: Woods, Gina, et al.
Publicado: (2019)

MON-104 Defining the Contribution of Weight to the Extent of Metabolic Disease in FPLD: Insights from a Retrospective "Matched" Case-Control Study
por: Koo, Eden, et al.
Publicado: (2019)

SAT-102 Self-efficacy As A Predictor Of Weight Loss In Veterans With Obesity Participating In Medical Weight Management.
por: Parziale, Andrew, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pjoqsa8lblsr3jnrd18md0iprb